IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Study sponsor: IO Biotech
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-05-30Actual
Enrollment · participants407Actual
Source updated2025-08-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.